Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study
Identifieur interne : 000678 ( Main/Exploration ); précédent : 000677; suivant : 000679Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study
Auteurs : N. Inagaki [Japon] ; K. Kondo [Japon] ; T. Yoshinari [Japon] ; N. Maruyama [Japon] ; Y. Susuta [Japon] ; H. Kuki [Japon]Source :
- Diabetes, Obesity and Metabolism [ 1462-8902 ] ; 2013-12.
Abstract
We examined the efficacy, safety and tolerability of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in Japanese patients with type 2 diabetes (T2DM) undergoing diet and exercise therapy.
Url:
DOI: 10.1111/dom.12149
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001241
- to stream Istex, to step Curation: 001217
- to stream Istex, to step Checkpoint: 000335
- to stream Main, to step Merge: 000679
- to stream Main, to step Curation: 000678
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study</title><author><name sortKey="Inagaki, N" sort="Inagaki, N" uniqKey="Inagaki N" first="N." last="Inagaki">N. Inagaki</name></author><author><name sortKey="Kondo, K" sort="Kondo, K" uniqKey="Kondo K" first="K." last="Kondo">K. Kondo</name></author><author><name sortKey="Yoshinari, T" sort="Yoshinari, T" uniqKey="Yoshinari T" first="T." last="Yoshinari">T. Yoshinari</name></author><author><name sortKey="Maruyama, N" sort="Maruyama, N" uniqKey="Maruyama N" first="N." last="Maruyama">N. Maruyama</name></author><author><name sortKey="Susuta, Y" sort="Susuta, Y" uniqKey="Susuta Y" first="Y." last="Susuta">Y. Susuta</name></author><author><name sortKey="Kuki, H" sort="Kuki, H" uniqKey="Kuki H" first="H." last="Kuki">H. Kuki</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7CD01016BA2B7C47AEB2F9A2E917D042FC65156C</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/dom.12149</idno><idno type="url">https://api.istex.fr/document/7CD01016BA2B7C47AEB2F9A2E917D042FC65156C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001241</idno><idno type="wicri:Area/Istex/Curation">001217</idno><idno type="wicri:Area/Istex/Checkpoint">000335</idno><idno type="wicri:doubleKey">1462-8902:2013:Inagaki N:efficacy:and:safety</idno><idno type="wicri:Area/Main/Merge">000679</idno><idno type="wicri:Area/Main/Curation">000678</idno><idno type="wicri:Area/Main/Exploration">000678</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study</title><author><name sortKey="Inagaki, N" sort="Inagaki, N" uniqKey="Inagaki N" first="N." last="Inagaki">N. Inagaki</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Diabetes and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Kondo, K" sort="Kondo, K" uniqKey="Kondo K" first="K." last="Kondo">K. Kondo</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Mitsubishi Tanabe Pharma Corporation, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Yoshinari, T" sort="Yoshinari, T" uniqKey="Yoshinari T" first="T." last="Yoshinari">T. Yoshinari</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Mitsubishi Tanabe Pharma Corporation, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Japon</country></affiliation></author><author><name sortKey="Maruyama, N" sort="Maruyama, N" uniqKey="Maruyama N" first="N." last="Maruyama">N. Maruyama</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Mitsubishi Tanabe Pharma Corporation, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Susuta, Y" sort="Susuta, Y" uniqKey="Susuta Y" first="Y." last="Susuta">Y. Susuta</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Mitsubishi Tanabe Pharma Corporation, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Kuki, H" sort="Kuki, H" uniqKey="Kuki H" first="H." last="Kuki">H. Kuki</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Mitsubishi Tanabe Pharma Corporation, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Diabetes, Obesity and Metabolism</title><title level="j" type="abbrev">Diabetes Obes Metab</title><idno type="ISSN">1462-8902</idno><idno type="eISSN">1463-1326</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2013-12">2013-12</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1136">1136</biblScope><biblScope unit="page" to="1145">1145</biblScope></imprint><idno type="ISSN">1462-8902</idno></series><idno type="istex">7CD01016BA2B7C47AEB2F9A2E917D042FC65156C</idno><idno type="DOI">10.1111/dom.12149</idno><idno type="ArticleID">DOM12149</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1462-8902</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">We examined the efficacy, safety and tolerability of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in Japanese patients with type 2 diabetes (T2DM) undergoing diet and exercise therapy.</div></front></TEI><affiliations><list><country><li>Japon</li></country><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><noRegion><name sortKey="Inagaki, N" sort="Inagaki, N" uniqKey="Inagaki N" first="N." last="Inagaki">N. Inagaki</name></noRegion><name sortKey="Kondo, K" sort="Kondo, K" uniqKey="Kondo K" first="K." last="Kondo">K. Kondo</name><name sortKey="Kuki, H" sort="Kuki, H" uniqKey="Kuki H" first="H." last="Kuki">H. Kuki</name><name sortKey="Maruyama, N" sort="Maruyama, N" uniqKey="Maruyama N" first="N." last="Maruyama">N. Maruyama</name><name sortKey="Susuta, Y" sort="Susuta, Y" uniqKey="Susuta Y" first="Y." last="Susuta">Y. Susuta</name><name sortKey="Yoshinari, T" sort="Yoshinari, T" uniqKey="Yoshinari T" first="T." last="Yoshinari">T. Yoshinari</name><name sortKey="Yoshinari, T" sort="Yoshinari, T" uniqKey="Yoshinari T" first="T." last="Yoshinari">T. Yoshinari</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000678 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000678 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7CD01016BA2B7C47AEB2F9A2E917D042FC65156C
|texte= Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study
}}
| This area was generated with Dilib version V0.6.25. |  |